把三张表、经营指标、SEC / 巨潮 / 港交所原始财报、业绩材料和电话会放到同一条可核验时间线上。 披露事实、结构化补位值与派生指标分开标注,缺失逐字稿不会用摘要或模型生成内容补齐。
单季、累计、年度和资产负债表时点分开保存;每个数值都保留单位、申报日、表单、XBRL 概念或原始中文字段。
美股链接 SEC 法定申报和发行人 IR,A 股链接巨潮原始 PDF,港股链接港交所披露易原始年报与中报。分部、订单、产能和客户集中度只在有可核验披露时展示。
官方电话会入口与已授权逐字稿分开。没有合法取得的全文时只显示材料可用性,不生成或拼接虚假的逐字稿。
三张表会执行资产负债、毛利润、税前利润等勾稽检查;超出容差的记录保留原值并标记警告, 不会为了让公式“对上”而修改公司披露。
| 2026-04-30 |
| 3/3 |
| $59.43M |
| -$1.18M |
| -$5.04M |
| 48.0% |
| -1.9% |
| 61 |
| 尚无授权文本 |
| AKTS Aktis Oncology, Inc. | 2026-03-31 | 3/3 | $3.23M | -$18.33M | -$26.1M | — | -703.6% | 6 | 尚无授权文本 |
| ALXO ALX ONCOLOGY HOLDINGS INC | 2026-03-31 | 3/3 | — | -$17.93M | -$18.7M | — | — | 85 | 尚无授权文本 |
| BBOT BridgeBio Oncology Therapeutics, Inc. | 2026-03-31 | 3/3 | — | -$42.11M | -$35.94M | — | — | 26 | 尚无授权文本 |
| CGON CG Oncology, Inc. | 2026-03-31 | 3/3 | — | -$60.2M | -$57.25M | — | — | 38 | 尚无授权文本 |
| CHRS Coherus Oncology, Inc. | 2026-03-31 | 3/3 | — | -$38.33M | — | — | — | 116 | 尚无授权文本 |
| CON Concentra Group Holdings Parent, Inc. | 2026-03-31 | 3/3 | $569.56M | $50.49M | $9.93M | — | 16.8% | 33 | 尚无授权文本 |
| CRDF Cardiff Oncology, Inc. | 2026-03-31 | 3/3 | $41,000 | -$12.35M | — | — | -31341.5% | 115 | 尚无授权文本 |
| CTOR CITIUS ONCOLOGY, INC. | 2026-03-31 | 3/3 | $1.67M | -$26.61M | — | 80.3% | -1716.2% | 62 | 尚无授权文本 |
| GBR New Concept Energy, Inc. | 2026-03-31 | 3/3 | $39,000 | -$14,000 | — | — | -130.8% | 64 | 尚无授权文本 |
| KURA Kura Oncology, Inc. | 2026-03-31 | 3/3 | $18.27M | -$73.33M | -$85.98M | 98.6% | -431.5% | 97 | 尚无授权文本 |
| NTHI NEONC TECHNOLOGIES HOLDINGS, INC. | 2026-03-31 | 3/3 | — | -$8.82M | — | — | — | 47 | 尚无授权文本 |
| OFRM Once Upon a Farm, PBC | 2026-03-31 | 3/3 | $72.72M | -$15.81M | -$14.29M | 40.8% | -22.2% | 8 | 尚无授权文本 |
| ONC BeOne Medicines Ltd. | 2026-03-31 | 3/3 | $1.51B | $227.36M | $160.55M | 89.0% | 16.5% | 182 | 尚无授权文本 |
| ONCH 1RT Acquisition Corp. | 2026-03-31 | 3/3 | — | $1.37M | — | — | — | 7 | 尚无授权文本 |
| ONCHU 1RT Acquisition Corp. | 2026-03-31 | 3/3 | — | $1.37M | — | — | — | 7 | 尚无授权文本 |
| ONCO Onconetix, Inc. | 2026-03-31 | 3/3 | $21,457 | -$4.21M | — | -7.7% | -47657.2% | 135 | 尚无授权文本 |
| ONCY ONCOLYTICS BIOTECH INC | 2026-03-31 | 3/3 | — | -$9.24M | -$7.3M | — | — | 229 | 尚无授权文本 |
| PDLB Ponce Financial Group, Inc. | 2026-03-31 | 3/3 | — | $8.62M | $13.83M | — | — | 77 | 尚无授权文本 |
| PYXS Pyxis Oncology, Inc. | 2026-03-31 | 3/3 | — | -$23.27M | — | — | — | 71 | 尚无授权文本 |
| TMCI TREACE MEDICAL CONCEPTS, INC. | 2026-03-31 | 3/3 | $47.2M | -$17.96M | $4.18M | 79.3% | -36.4% | 67 | 尚无授权文本 |
| TOI Oncology Institute, Inc. | 2026-03-31 | 3/3 | $147.44M | -$2.49M | -$3.26M | — | -4.4% | 96 | 尚无授权文本 |
| CCM Concord Medical Services Holdings Ltd | 2025-12-31 | 3/3 | $64.97M | -$13.27M | -$36.92M | 5.7% | -57.6% | 59 | 尚无授权文本 |
| NCI Neo-Concept International Group Holdings Ltd | 2025-12-31 | 3/3 | $17.63M | $42,615 | $2.23M | 36.9% | 1.3% | 35 | 尚无授权文本 |